Coronavirus Infectious Disease Ontology
32519 terms(s) returned
| Term Type: | Record: 6401 to 6450 of 32519 Records | Page: 129 of 651, First Previous Next Last | Show Records Per Page |
- SARS-COV-2 (COVID-19) vaccine mRNA spike protein LNP bivalent booster preservative free 30 mcg/0.3 mL dose tris-sucrose formulation
- SARS-COV-2 (COVID-19) vaccine mRNA spike protein LNP bivalent booster preservative free 50 mcg/0.5 mL or 25 mcg/0.25 mL dose
- SARS-COV-2 (COVID-19) vaccine mRNA spike protein LNP bivalent preservative free 3 mcg/0.2 mL dose tris-sucrose formulation
- SARS-COV-2 (COVID-19) vaccine mRNA spike protein LNP preservative free 10 mcg/0.2mL dose tris-sucrose formulation
- SARS-COV-2 (COVID-19) vaccine mRNA spike protein LNP preservative free 100 mcg/0.5mL dose or 50 mcg/0.25mL dose
- SARS-COV-2 (COVID-19) vaccine mRNA spike protein LNP preservative free 3 mcg/0.2mL dose tris-sucrose formulation
- SARS-COV-2 (COVID-19) vaccine mRNA spike protein LNP preservative free 30 mcg/0.3mL dose
- SARS-COV-2 (COVID-19) vaccine mRNA spike protein LNP preservative free 30 mcg/0.3mL dose tris-sucrose formulation
- SARS-COV-2 (COVID-19) vaccine mRNA spike protein LNP preservative free 50 mcg/0.5 mL dose
- SARS-COV-2 (COVID-19) vaccine mRNA spike protein LNP preservative free pediatric 25 mcg/0.25 mL dose
- SARS-COV-2 (COVID-19) vaccine mRNA spike protein LNP preservative free pediatric 50 mcg/0.5 mL dose
- SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, bivalent booster, preservative free, 30 mcg/0.3 mL dose, tris-sucrose formulation
- SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 30 mcg/0.3mL dose
- SARS-COV-2 COVID-19 Non-US Vaccine Specific Product Unknown
- SARS-COV-2 COVID-19 Protein Subunit Non-US Vaccine Product (Anhui Zhifei Longcom Biopharmaceutical + Institute of Microbiology Chinese Academy of Sciences)
- SARS-COV-2 COVID-19 Protein Subunit Non-US Vaccine Product (Anhui Zhifei Longcom Zifivax)
- SARS-COV-2 COVID-19 Protein Subunit Non-US Vaccine Product (Jiangsu Province Centers for Disease Control and Prevention)
- SARS-COV-2 COVID-19 Viral Vector Non-replicating Non-US Vaccine Product (CONVIDECIA) CanSino Biological Inc./Beijing Institute of Biotechnology
- SARS-COV-2 COVID-19 Viral Vector Non-replicating Non-US Vaccine Product (Sputnik Light)
- SARS-COV-2 COVID-19 mRNA bivalent original/Omicron BA.1 Non-US Vaccine (Spikevax Bivalent) Moderna
- SARS-COV-2 COVID-19 mRNA bivalent original/Omicron BA.1 Non-US Vaccine Product (Comirnaty Bivalent) Pfizer-BioNTech
- SARS-COV-2 COVID-19 mRNA, bivalent, original/Omicron BA.1, Non-US Vaccine Product (Comirnaty Bivalent), Pfizer-BioNTech
- SARS-COV-2 R-GENE
- SARS-CoV Baculovirus S protein Vaccine
- SARS-CoV E gene mutant vaccine
- SARS-CoV binding to host cell
- SARS-CoV disease process
- SARS-CoV entry to cell
- SARS-CoV epitope
- SARS-CoV laboratory host role
- SARS-CoV natural host role
- SARS-CoV pCI-N DNA vaccine
- SARS-CoV protein
- SARS-CoV replication inside cell
- SARS-CoV shedding
- SARS-CoV transmission
- SARS-CoV-2 AY.1 virus
- SARS-CoV-2 AY.2 virus
- SARS-CoV-2 Alpha variant
- SARS-CoV-2 B.1.135 virus
- SARS-CoV-2 B.1.135.2 virus
- SARS-CoV-2 B.1.135.3 virus
- SARS-CoV-2 B.1.617.2 virus
- SARS-CoV-2 B.1.7 virus
- SARS-CoV-2 BA.1 virus
- SARS-CoV-2 BA.2 virus
- SARS-CoV-2 BA.2.12.1 virus
- SARS-CoV-2 BA.4 virus
- SARS-CoV-2 BA.5 virus
- SARS-CoV-2 Beta variant
